Sanofi’s quadrivalent flu vaccine approved by US FDA

The FDA has approved Sanofi Pasteur’s supplemental biologics license application (sBLA) for licensure of its four-strain influenza vaccine, Fluzone Quadrivalent.

Sanofi Pasteur is the vaccines division of Sanofi. Like the division’s Fluzone vaccine, which is administered to over 50 million people in the US each year, Fluzone Quadrivalent is licensed for use in children six months of age and older, adolescents and adults.

Fluzone Quadrivalent includes two A strains and two B strains to help protect against influenza disease. It will be available in the US in time for the 2013 influenza season.

“Sanofi Pasteur is committed to providing new immunization options for the prevention of influenza to help healthcare providers meet the specific immunization needs of all types of patients, and we are excited to introduce Fluzone Quadrivalent vaccine as an important new addition to our Fluzone family of specialized influenza vaccines.
“Protection against the type B flu strain may be an especially important factor that healthcare providers consider when immunizing children since influenza B causes a substantial number of illnesses, hospitalizations and deaths in the pediatric population.”

David Greenberg, MD, Vice President U.S. Scientific and Medical Affairs, Sanofi Pasteur.

Sanofi’s 4-in-1 influenza vaccine joins GlaxoSmithKline’s Fluarix Quadrivalent and AstraZeneca’s MedImmune FluMist Quadrivalent that are already approved for use in the United States.

 

 

Related news:

FDA approves Sanofi Pasteur influenza vaccine (Reuters)

Reference links:

Sanofi press release

Don't miss your daily pharmaphorum news.
SUBSCRIBE free here.